Abstract: Palmoplantar psoriasis is a rare phenotype of plaque psoriasis that is easy to miss and misdiagnose, and traditional treatments are often ineffective.IL-17 inhibitors are effective as biologics in palmoplantar psoriasis, but there is attenuation of efficacy, dose dependence, and intolerability in some patients. JAK inhibitors could affect a series of cytokines by inhibiting the JAK-STAT pathway, and play an immunomodulatory role. In this paper, we report a case of palmoplantar psoriasis resistant to secukinumab treated with JAK inhibitor tofacitinib, and achieved good results.

Key words: tofacitinib')">">tofacitinib, palmoplantar psoriasis, JAK inhibitor, IL-17 inhibitor